<PAGE>
FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of l~34
Date of Report (Date of earliest event reported)
November 10, 1997
ROBERTS PHARMACEUTICAL CORPORATION
- --------------------------------------------------------------------------------
(exact name of registrant as specified in its charter)
NEW JERSEY 1-1-432 22-2429994
- ----------------- ------------- ----------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification
incorporation) Number)
Meridian Center II
4 Industrial Way West
Eatontown, New Jersey 07724
- --------------------------------------------------------------------------------
(Address of principal executive offices, including zip code)
Registrant's telephone number, including area code: 908-389-1182
Meridian Center II
4 Industrial Way West
Eatontown, New Jersey 07724
- --------------------------------------------------------------------------------
(Former name or former address, if changed from last report)
<PAGE>
-2-
Item 5. Other Events
------------
Roberts Pharmaceutical Corporation announced today the successful
completion of a Phase la study of LY315535, a gastrointestinal (GI) compound
acquired from Lilly. The compound is being developed by Roberts for the
treatment of Functional Bowel Disorders.
The Phase la single rising dose study in human volunteers was conducted
for Roberts by PPD Pharmaco (Austin, Texas). The objectives of the placebo-
controlled study were to 1) show safety across a range of doses and 2) establish
a maximum tolerated dose. The study demonstrated a favorable safety profile with
LY315535 being well-tolerated across a broad range of doses. The next stage of
Phase I testing in humans is scheduled to commence shortly.
LY315535 is a novel compound which acts as both a muscarinic receptor
antagonist and as a serotonin (5-HT) receptor agonist with a high degree of
selectivity for the 5-HTlA receptor subtype. LY315535 is a potentially potent,
orally administrated drug which is much needed in a large and generally
unsatisfied GI market.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ROBERTS PHARMACEUTICAL CORPORATION
----------------------------------
(Registrant)
Date: November 14, 1997 By: /s/ Anthony A. Rascio
-------------------------------
Anthony A. Rascio
Vice President
